China In-Vitro Diagnostics (IVD) Market, Size, Share, Trends, Regulations, Reimbursement & Key Players Analysis - Forecast to 2026

iGATE Research has released a report on "China In-Vitro Diagnostics (IVD) Market, Size, Share, Trends, Regulations, Reimbursement & Key Players Analysis - Forecast to 2026"

Click here to view the complete report: https://www.igateresearch.com/china-in-vitro-diagnostics-ivd-market-size-share-trends-regulations-reimbursement-key-players-analysis-forecast-to-2026.html

China In-Vitro Diagnostics (IVD) market is likely to reach around US$ 17.6 Billion by 2026. China represents one of the largest clinical laboratory markets in the Asia-Pacific region, and the fastest growing among the top ten IVD country markets. Historically, large multinational companies have dominated IVD market in China; today, domestic companies such as Shanghai Kehua Bio-Engineering (KHB) being one of the largest - are now gaining market share.

China is a large and fast-growing in vitro diagnostics (IVD) market - in fact, only second to the United States in terms of value. China's quickly aging population means the country is experiencing an explosion of chronic conditions such as diabetes, heart disease and cancer. All of these conditions can be diagnosed and monitored using IVD products. Further, the average Chinese consumer is now willing and able to pay more for healthcare than a decade years ago. Hence, China has the potential for more dramatic growth in the future.

China IVD Market Segment Wise Analysis

o Immunoassay captures maximum share of the China IVD market.

o Clinical Chemistry holds the 2nd position in China IVD market being followed by Molecular Testing.

o The molecular testing market in China is expected to show double digits growth rate during the forecast period.

o China SMBG market is dominated by foreign IVD companies such as Roche.

o Microbiology and Hematology segments are competing closely with each other to grab maximum share of the pie.

o Point of Care Testing accounts for least share of the China IVD market.

China IVD Market Company Analysis

o Roche captures maximum share of the China IVD market.

o Sysmex Corporation and Mindary Medical are other top two players in the China IVD market.

o Sysmex has built a robust infrastructure in China, working with more than 200 sales distributors to provide products and services throughout the country.

o In Abbott's worldwide diagnostics business, sales growth over the last three years reflected the acquisition of Alere in October of 2017.

o At present, many local players are present in China IVD market and their combined market share is likely to exceed 60 percent by 2026.

iGATE RESEARCH report titled "China In-Vitro Diagnostics (IVD) Market, Size, Share, Trends, Regulations, Reimbursement & Key Players Analysis - Forecast to 2026" provides a comprehensive analysis of the China In-Vitro Diagnostics (IVD) Market.

This 108 Page report with 34 Figures and 3 Tables has been analyzed from 10 View Points:

1) China IVD Market and Forecast (2010 - 2026)
2) China IVD Market Share and Forecast (2010 - 2026)
3) China IVD Market & Forecast - By Segment (2010 - 2026)
4) Development Environment and Regulatory Status in China IVD market
5) China IVD Market & Forecast - Key Players Sales Analysis (2010 - 2026)
6) Registration for In Vitro Diagnostic Reagents in China
7) Regulatory History/Status/Trends in China IVD Market
8) Reimbursement of IVD Products in China
9) Profiles of Select Private Clinical Labs and Diagnostic Services Companies
10) China IVD Industry Drivers & Challenges

China IVD Market - By Application Segments

1. Clinical Chemistry Market
2. Immunoassay Market
3. Hematology Market
4. Coagulation Market
5. Microbiology Market
6. Molecular Testing Market
7. Self-Monitoring of Blood Glucose (SMBG) Market
8. Point of Care Testing (POCT) Market

China IVD Sales & Forecast - Key Players Analysis

1. Roche Diagnostics
2. Abbott Laboratories
3. Sysmex Corporation
4. Mindray Medical International Limited
5. Shanghai Kehua Bio-Engineering Co. Ltd.
6. Others

Profiles of Private Clinical Labs and Diagnostic Services Companies in China

o Dian Diagnostics Group Co. Ltd. (Formerly Zhejiang Di'an Diagnostics Technology Co., Ltd.)
o ADICON Clinical Laboratories
o Guangzhou Kingmed Diagnostics Center Co. Ltd.
o Kindstar Global
o BGI-Shenzhen
o OriGene Technologies

Data Source

iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.

Research Methodologies

Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.

Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government and NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries and Local Councils and a large number of Paid Databases.

Contact US
iGATE Research PVT LTD

Ravi Sinha
Sales Manager
Marketing and Sales Divison
Email: ravi.sinha@igateresearch.com
Contact: +91-858-684-0791, +91-821-092-7469 (INDIA)
Web: www.igateresearch.com

WZ-1 Tagore Garden,New Delhi, India

GATE Research is a global specialist in the field of Market Research, Analytics and Consulting Services.
We serve as a one stop shop for all the market and industry research needs including Syndicated Research, Customized Research and Analytics Services. iGATE Research is a gateway of information for various companies, whether it is building a Strategy, or identifying Business Opportunity, Product Expansion, Market/Business Expansion, Competition Assessment, etc. Combining deep understanding of the industry along with the expertise, we help our clients in making better Business decisions.

This release was published on openPR.